Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18502846 | 1.00 | LMNA (0.50) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL25474174 | 1.00 | LMNA (0.50) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL1573739 | 1.00 | LMNA (0.50) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL3582332 | 0.90 | HTR3E (0.46) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL9381779 | 0.90 | HTR3E (0.46) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL13778750 | 0.86 | LMNA (0.40) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL15444631 | 0.80 | HTR3A (0.34) | LMNACYP2C9HTR3A | |
| SCHEMBL20715143 | 0.80 | LMNA (0.46) | LMNACYP2C9SLC6A2CHRM1SLC6A4 | |
| SCHEMBL3408333 | 0.79 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL3411137 | 0.78 | HTR4 (0.31) | LMNACYP2C9HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021026451-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3617221-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME, AND PREPARATION METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2006135715-A1 | BENZTROPINAMINE ANALOGS AS DOPAMINE UPTAKE INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-0085893-B1 | PYRIDOBENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1986-05-14 | — | — | EP | disclosed |
| US-4443452-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
| US-4424222-A | ANTIULCER AND ANTISECRETORY AGENTS | KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4410527-A | ANTIULCER AGENTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-10-18 | — | — | US | disclosed |
| EP-0086980-A1 | Substituted dibenzodiazepinones, process for their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0086981-A1 | Substituted thienobenzodiazepinones, process for their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0085893-A2 | Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | LMNA 3908/4885CYP2C9 2253/4885SLC6A2 4839/4885 |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | LMNA 3892/4885CYP2C9 2743/4885SLC6A2 4861/4885 |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 3908/4885CYP2C9 2253/4885SLC6A2 4839/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 3892/4885CYP2C9 2743/4885SLC6A2 4861/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 3892/4885CYP2C9 2743/4885SLC6A2 4861/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | LMNA 3295/4885CYP2C9 781/4885SLC6A2 3156/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | LMNA 3908/4885CYP2C9 2253/4885SLC6A2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.